Abstract
This post hoc analysis of the COMPARZ study (pazopanib, n = 557; sunitinib, n = 553) supported similar efficacy of first-line pazopanib and first-line sunitinib treatment in advanced renal cell carcinoma. Patients who required dose modifications because of toxicity received higher cumulative doses with longer time of treatment and had significantly better objective response rate, progression-free survival, and overall survival than patients with minimal toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 425-435.e4 |
Journal | Clinical Genitourinary Cancer |
Volume | 17 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2019 |
Keywords
- First-line
- Sunitinib
- Tyrosine kinase inhibitor
- VEGF
- VEGFR
ASJC Scopus subject areas
- Oncology
- Urology